The University of Chicago Header Logo

Connection

Larry Goldstein to Fibrinolytic Agents

This is a "connection" page, showing publications Larry Goldstein has written about Fibrinolytic Agents.
Connection Strength

3.592
  1. Routine 24-Hour Computed Tomography Brain Scan is not useful in stable patients Post Intravenous Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2016 Mar; 25(3):540-2.
    View in: PubMed
    Score: 0.450
  2. Temporal changes in the external validity of clinical trials: asymptomatic carotid artery stenosis. Cerebrovasc Dis. 2014; 38(3):174-5.
    View in: PubMed
    Score: 0.416
  3. Modern medical management of acute ischemic stroke. Methodist Debakey Cardiovasc J. 2014 Apr-Jun; 10(2):99-104.
    View in: PubMed
    Score: 0.401
  4. Poststroke pharmacotherapy: another ictus. Stroke. 2012 Dec; 43(12):3433-5.
    View in: PubMed
    Score: 0.364
  5. Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes. 2011 Jan 01; 4(1):30-8.
    View in: PubMed
    Score: 0.318
  6. Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician. J Thromb Thrombolysis. 2010 Apr; 29(3):368-77.
    View in: PubMed
    Score: 0.304
  7. Primum non nocere: antithombotics after intracerebral hemorrhage? Neurology. 2006 Jan 24; 66(2):162-3.
    View in: PubMed
    Score: 0.227
  8. Association of Antithrombotic Drug Use With Incident Intracerebral Hemorrhage Location. Neurology. 2024 Jun 25; 102(12):e209442.
    View in: PubMed
    Score: 0.202
  9. IV tPA for acute ischemic stroke: Times are changing. Neurology. 2016 11 22; 87(21):2178-2179.
    View in: PubMed
    Score: 0.120
  10. Chronic kidney disease and stroke. Adv Chronic Kidney Dis. 2014 Nov; 21(6):500-8.
    View in: PubMed
    Score: 0.104
  11. Author response. Neurology. 2014 Jan 07; 82(1):95.
    View in: PubMed
    Score: 0.099
  12. Interventional and new approaches to stroke prevention: introduction. Stroke. 2013 Jun; 44(6 Suppl 1):S37.
    View in: PubMed
    Score: 0.095
  13. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 May 28; 80(22):2065-9.
    View in: PubMed
    Score: 0.094
  14. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012 Dec; 43(12):3442-53.
    View in: PubMed
    Score: 0.089
  15. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011 Sep; 42(9):2645-50.
    View in: PubMed
    Score: 0.084
  16. Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? Cerebrovasc Dis. 2009; 27(3):254-8.
    View in: PubMed
    Score: 0.070
  17. Acute ischemic stroke treatment in 2007. Circulation. 2007 Sep 25; 116(13):1504-14.
    View in: PubMed
    Score: 0.064
  18. Statewide assessment of hospital-based stroke prevention and treatment services in North Carolina: changes over the last 5 years. Stroke. 2003 Dec; 34(12):2945-50.
    View in: PubMed
    Score: 0.049
  19. Guidelines on the use of thrombolytic agents in stroke. JAMA. 1995 Jul 19; 274(3):218.
    View in: PubMed
    Score: 0.027
  20. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003 Apr; 34(4):1056-83.
    View in: PubMed
    Score: 0.012
  21. Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. Stroke. 1990 Sep; 21(9):1289-92.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.